Peptide FDA Compounding Status Tracker 2026 — Complete 503A Guide

1PCAC & Regulatory Timeline

The July 2026 hearings are done; what matters now is FDA rulemaking on the six peptides the committee recommended, and the second PCAC meeting before the end of February 2027. A committee vote is advisory; a peptide is only on the 503A Bulks List once FDA issues a final rule.

1. Late 2026 – 2027Watch
   FDA Rulemaking on the Six Recommended Peptides

   FDA must publish a proposed rule in the Federal Register and take public comment before any recommended peptide is added to the 503A Bulks List. The committee's votes are advisory; FDA can still decline to list a substance.

   BPC-157KPVTB-500MOTs-CSemaxEpitalon
2. July 23, 2026Held
   PCAC Meeting — Day 1

   Committee voted to recommend all four for the 503A Bulks List (BPC-157, KPV and TB-500 8–6 with 1 abstention; MOTS-c 7–5 with 2 abstentions), against FDA staff's proposal.

   BPC-157KPVMOTs-CTB-500
3. July 24, 2026Held
   PCAC Meeting — Day 2

   Committee recommended Semax (8–5–1) and Epitalon (7–4–1); voted against emideltide/DSIP (6–7–1).

   Emideltide (DSIP)EpitalonSemax
4. Before February 2027Announced
   Second PCAC Meeting — Additional Peptides

   FDA has announced a second PCAC meeting to review five more peptides for possible 503A inclusion. LL-37, Dihexa, Melanotan II, and PEG-MGF were previously withdrawn with no active review — now reconsidered. Exact date TBD (before the end of February 2027).

   Cathelicidin LL-37GHK-CuDihexa AcetateMelanotan IIPEG-MGF

2Peptides Under FDA Review — Full Status Table

All peptides currently under FDA review for 503A compounding eligibility. Use the color-coded badges to identify each peptide’s review stage. Peptides removed from Category 2 and sent to PCAC are listed first, followed by Category 1 peptides still under standard evaluation.

← Scroll to see all columns →

3Understanding FDA 503A Categories

The FDA uses a category system to organize bulk drug substances nominated for compounding under Section 503A. Here’s what each means for peptide access.

What does “Approved for 503A Compounding” mean?

When a substance is approved for 503A compounding, licensed pharmacies can legally prepare customized formulations for individual patients with a valid prescription. This is distinct from FDA-approved manufactured drugs — compounded medications are not FDA-approved products themselves, but are prepared under the framework governing pharmacy compounding. Approval ensures adequate safety, quality, and clinical evidence exists to support the substance’s use in patient care.

How PCAC hearings work

The PCAC follows a structured process: the FDA presents its safety and clinical review; public stakeholders submit testimony; and committee members discuss and vote on a recommendation. The FDA is not bound by PCAC recommendations but historically follows them in the majority of cases. Final determinations are typically issued weeks to months after the vote.

4What This Means for Patients

If you’re using — or considering — peptide therapy, here’s how to protect your access to care as the regulatory landscape evolves.

• ✓If you’re currently using a peptide on this list, don’t panic. Category 1 peptides remain available through compounding pharmacies while under evaluation. For peptides the PCAC has voted on, a recommendation is not a listing: confirm current availability with your prescriber and compounding pharmacy before relying on it.
• ✓Work only with legitimate 503A compounding pharmacies — state-licensed, FDA-registered pharmacies that compound pursuant to valid prescriptions. Avoid unregulated “research chemical” suppliers. Find a compounding pharmacy →
• ✓Always work with a licensed prescribing provider. Peptide therapy requires medical oversight — lab monitoring, dosage adjustments, and follow-up — to ensure it’s safe and appropriate for you. Consult a peptide specialist →
• ✓PCAC outcomes are not final until the FDA acts. Even after a recommendation, the FDA must issue a formal determination — there’s often a window between the hearing and final action where substances remain accessible.
• ✓Engage in the public comment process. If a peptide you depend on is scheduled for review, submit a public comment to the FDA docket — patient testimonials carry weight. Check regulations.gov for open comment periods.

5In-Depth FDA Peptide Articles

Go deeper on specific peptides, PCAC mechanics, and what the 2026 decisions mean for patients and providers.

6Frequently Asked Questions

• What is FDA 503A Category 1 for peptides?

  Category 1 substances are currently under evaluation by the FDA. While under review, these peptides can still be legally compounded by registered 503A pharmacies under a valid prescription. Category 1 status does not imply safety concerns — it simply means the FDA has not yet completed its review.

• What is FDA 503A Category 2 for peptides?

  Category 2 substances have been flagged with potential safety or quality concerns. Compounding of these substances is restricted while they undergo further review by the Pharmacy Compounding Advisory Committee (PCAC). A PCAC hearing must take place before a final determination is made.

• What did the July 2026 PCAC meeting decide?

  On July 23–24, 2026 the committee voted to recommend adding BPC-157, KPV, TB-500, MOTS-c, Semax and Epitalon (free base and acetate) to the 503A Bulks List, and voted against emideltide (DSIP). FDA staff had recommended against all seven. The votes are advisory; none of the seven is on the list until FDA completes rulemaking.

• What is the PCAC and how does it affect peptide access?

  The Pharmacy Compounding Advisory Committee (PCAC) is an FDA advisory body that reviews nominated bulk drug substances for use in compounding. The PCAC holds public hearings, reviews clinical evidence, and makes recommendations to the FDA on whether substances should be approved for 503A compounding. Their recommendations heavily influence final FDA decisions on peptide availability.

• Can I still get compounded peptides in 2026?

  Yes. Many peptides remain available through legitimate 503A compounding pharmacies under a valid prescription while they are under FDA evaluation (Category 1). Peptides in Category 2 or under active PCAC safety review may have restricted availability. Always work with a licensed prescribing provider and a registered compounding pharmacy.

• What happens after PCAC reviews a peptide?

  The committee's vote is advisory. To add a substance to the 503A Bulks List, FDA must publish a proposed rule in the Federal Register, take public comment, and issue a final rule, which can take a year or more. FDA is not bound by the vote and can decline to list a substance. Until a final rule lists it, a recommended peptide is not on the 503A Bulks List.